Adams Clinical Announces Appointment of Dr. Colin Sauder as Chief Scientific Officer and Expansion of Clinical Team to Support Strategic Growth

Adams Clinical Site Network (“Adams”, or the “Company”), a leading Neuroscience-focused clinical trial site network announced today that Dr. Colin Sauder, PhD has joined the company as Chief Scientific Officer. In his role, Dr. Sauder will oversee clinical and operational teams critical to the company’s strategic growth, including Principal Investigators and Clinical Operations across all Adams Clinical site locations.

Dr. Sauder held a pivotal clinical science role at Karuna Therapeutics supporting the late-phase Schizophrenia development program and NDA submission for KarXT, which went on to receive approval as Cobenfy (xanomeline and trospium). Following Karuna's acquisition by Bristol Meyers Squibb, Dr. Sauder was promoted to Head of Late-Stage Clinical Science, Neuropsychiatry. He received his PhD in Clinical Psychology from Stony Brook University and served on the Psychiatry faculty at the University of Texas Health Science Center at San Antonio.

“Adams Clinical is poised to capitalize on a track-record of operational excellence and quality by design, and I am thrilled to be joining to help grow the company’s site footprint and expansion into new areas. Adams Clinical is building a replicable model that limits inter- and intra-site variability through centralization of key functions including recruitment, clinical and operational oversight,” said Dr. Sauder. “At Karuna, I had first-hand experience working with clinical trial sites to deliver successful results, and have witnessed the good, bad and ugly of site performance. In my experience, there is a striking shortage of sites that can consistently deliver high-quality data at scale in the Neuroscience space. I came to Adams to help build the site network that I would have confidently chosen as a strategic partner to deliver on Neuroscience programs as a sponsor.”

Dr. Steve Brannan, an industry veteran in Schizophrenia drug development and former Chief Medical Officer of Karuna Therapeutics, said, “One of Dr. Sauder’s greatest strengths as a drug developer is his understanding of site operations and the importance of site relationships and management to delivering successful trial outcomes. I believe that Colin’s experience and leadership will be impactful for Adams Clinical as they expand, and I am excited to see an increase in the number of quality neuroscience-focused sites in the United States.”

Adams Clinical has already made key hires in Principal Investigator roles to support Adams Clinical’s ongoing expansion in 2025, including investigators with a wealth of industry and academic clinical trial experience in Inpatient and Outpatient Psychiatry and Neurology:

• Dr. Rachel Noone, MD has joined Adams Clinical Harlem
• Dr. Ben Kurian, MD has joined to support growth in the Dallas area
• Dr. Cassie Blanchard, PhD will be the lead investigator at Adams Clinical’s planned new Philadelphia location, opening in Spring 2025

“We are thrilled to bring Dr. Sauder’s wealth of clinical development knowledge to our leadership team,” said Chris Reef, CEO of Adams Clinical. “Our mission to accelerate development of life-changing medicines with uncompromising commitment to data quality and rapid, diverse enrollment requires a team that is passionate about trial execution and uncompromising on safety, data integrity, and quality. Dr. Sauder’s role will be critical in helping Adams deliver on our strategic growth objectives to support the sponsor companies and trial participants that we serve.”

The Adams Clinical Site Network team will be available for meetings at the upcoming Schizophrenia International Research Society (SIRS) Congress in Chicago, which may be scheduled through the listed Press contact.

About Adams Clinical

Adams Clinical is the preeminent site network for enrollment speed and data quality in clinical trials for diseases of the central nervous system, with clinical trial sites embedded in vibrant, diverse communities throughout the United States. The Company’s depth of expertise, best-in-class technologies, and market-leading recruitment and retention to accelerate high-quality evidence generation and time-to-data for Pharmaceutical and Biotech companies, CROs and clinical trial participants.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250328257239/en/